ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2816

An Expanded Granzyme K+ CD8 T Cell Population Induces Inflammatory Responses in Rheumatoid Arthritis Synovium

Anna Helena Jonsson1, Fan Zhang 2, Gerald Watts 2, Kevin Wei 1, Deepak Rao 2, Soumya Raychaudhuri 2 and Michael Brenner 3, 1Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3Brigham and Women’s Hospital:, Boston

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Chemokine Receptors and CD8 cells, Rheumatoid arthritis (RA), synovial cells, synovial fluid, T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: 5T117: T Cell Biology & Targets in Autoimmune & Inflammatory Disease (2816–2821)

Session Type: ACR Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose: CD8 T cells represent nearly half of T cells in inflamed synovium from patients with rheumatoid arthritis (RA). Research to date has focused on CD4 T cells, yet we have found that synovial CD8 T cells express IFNgat a higher frequency and TNF at a similar frequency compared to CD4 T cells. Recent single-cell transcriptomic analysis of RA synovial tissue has suggested that CD8 T cells form sub-populations characterized by expression of secreted proteases granzyme K (GzmK) and granzyme B (GzmB).

Methods: We have assembled a single-cell RNA-seq data set of approximately 20,000 CD8 T cells by integrating new and publicly available data from synovial tissue (N=22) and fluid (N=1) from patients with RA and from blood (N=3) from healthy controls. RA patients met the 2010 ACR criteria for RA. Additional data were collected by flow cytometry or low-input RNA-seq from synovial tissue, synovial fluid, and blood from patients with clinical diagnoses of rheumatoid arthritis or healthy controls. In in vitro cultures, human synovial fibroblast cells were treated with recombinant granzyme K. Cytokine production was measured by ELISA, and reactive oxygen species were measured by a H2DCFDA fluorescence assay.

Results: At both the mRNA and protein levels, the vast majority of CD8 T cells in synovial tissue and fluid from patients with seropositive RA express GzmK, either alone or together with GzmB, a marked enrichment compared to blood (Figure 1). Very few synovial CD8 T cells express GzmB alone, which is the pattern seen in late differentiated cytotoxic T lymphocytes (CTLs). Unlike GzmB, GzmK does not activate apoptotic caspases. Instead, we find that GzmK has pro-inflammatory effects on synovial fibroblasts, inducing them to produce IL-6, CCL2, and reactive oxygen species (ROS), all of which are upregulated in inflamed synovium. GzmK+ CD8 T cells in blood express high frequencies of chemokine receptors CCR2, CCR5, and CXCR3, while CD8 T cells expressing GzmB alone express CX3CR1, suggesting that GzmK+ CD8 T cells and CTLs are recruited to sites of inflammation through different pathways. Interestingly, preliminary analysis of a large,integrated single-cell RNA-seq dataset of CD8 T cells from synovial tissue, synovial fluid, and blood shows selective expression of genes encoding Nur77, Ki67, and activation markers in distinct CD8 subsets, suggesting that some CD8 T cell subsets receive T-cell receptor (TCR)-mediated signals whereas others are activated through TCR-independent mechanisms.

Conclusion: The vast majority of CD8 T cells in RA synovial tissue and fluid express GzmK and express a phenotype and transcriptome distinct from typical GzmB+ CTLs. GzmK+ CD8 T cells appear to traffic to sites of inflammation using different chemokine receptors than CTLs. GzmK induces synovial fibroblasts to produce pro-inflammatory effector molecules including IL-6, CCL2, and ROS.  Preliminary analysis of a large single-cell RNA-seq data set suggests differential TCR-mediated and cytokine-mediate activation of CD8 T cell subsets in inflamed joints. Together, these findings form the basis of a new model of CD8 T cell migration and function in RA and potentially other rheumatologic diseases.

Figure 1. Frequencies of GzmK vs GzmB expression in blood from healthy controls and synovial fluid from patients with seropositive RA. Statistical comparison by Friedman test. * p<0.05 , *** p<0.001, **** p<0.0001.


Disclosure: A. Jonsson, Amgen, 2; F. Zhang, None; G. Watts, None; K. Wei, None; D. Rao, Janssen, 5, Merck, 2, Pfizer, 5; S. Raychaudhuri, None; M. Brenner, None.

To cite this abstract in AMA style:

Jonsson A, Zhang F, Watts G, Wei K, Rao D, Raychaudhuri S, Brenner M. An Expanded Granzyme K+ CD8 T Cell Population Induces Inflammatory Responses in Rheumatoid Arthritis Synovium [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/an-expanded-granzyme-k-cd8-t-cell-population-induces-inflammatory-responses-in-rheumatoid-arthritis-synovium/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/an-expanded-granzyme-k-cd8-t-cell-population-induces-inflammatory-responses-in-rheumatoid-arthritis-synovium/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology